DexCom (DXCM) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of DexCom (NASDAQ: DXCM) in the last few weeks:

• 1/12/2026 – DexCom had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
• 1/12/2026 – DexCom was downgraded by analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating. They now have a $71.00 price target on the stock, down previously from $80.00.
• 1/9/2026 – DexCom had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $86.00 price target on the stock, up previously from $84.00.
• 12/29/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – DexCom had its price target raised by analysts at Mizuho from $75.00 to $78.00. They now have an “outperform” rating on the stock.
• 12/16/2025 – DexCom had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $92.00 price target on the stock.
• 12/15/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/11/2025 – DexCom had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $77.00 price target on the stock, up previously from $75.00.
• 12/8/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – DexCom was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $75.00 price target on the stock, up previously from $63.00.
• 12/1/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – DexCom is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $68.00 price target on the stock.
• 11/24/2025 – DexCom had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – DexCom was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 11/16/2025 – DexCom was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.

Insider Buying and Selling

In other news, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 7,866 shares of company stock valued at $448,177 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.